Fig. 8: LINC01198 promotes melanoma resistance to vemurafenib in vivo. | Cell Death Discovery

Fig. 8: LINC01198 promotes melanoma resistance to vemurafenib in vivo.

From: LINC01198 activates Hippo signaling to stimulate IL-1β autocrine for driving vemurafenib resistance by associating with TAOK1/2 in melanoma

Fig. 8: LINC01198 promotes melanoma resistance to vemurafenib in vivo.

A Loss of LINC01198 sensitized melanoma to vemurafenib treatment in mouse xenograft model. B Tumor volumes (mm3) were plotted according to day. Mice were sacrificed at the end of the experiment and dissected tumors were shown. The expression levels of LINC01198 C and IL1B D in dissected xenografts were detected by qPCR. Statistical data of qPCR represented independent experiments ± s.d. E The protein levels of p-TAOK1/2/3, p-LATS1/2 and IL-1β were detected in xenografts after LINC01198 knockout with or without vemurafenib treatments by Western blot. F The amount of p-TAOK1/2//3, p-LATS1/2, IL-1β in tumor sections were evaluated using IHC staining. Scale bar, 50 µm. Data are presented as the means ± SD and p values are determined using two-tailed Student’s t-test. * p < 0.05; ** p < 0.01; *** p < 0.001.

Back to article page